USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
EPIVAX, INC.
Address:
146 CLIFFORD STREET
PROVIDENCE, RI
Phone:
N/A
URL:
N/A
EIN:
50499380
DUNS:
135531015
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $5,999,552.00 11
SBIR Phase II $1,474,236.00 1

Award List:

EPITOPE-DRIVEN HIV VACCINE TARGETING DENDRITIC CELLS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Anne S. Degroot
Abstract:
Not Available A hapten based upon the molecular structure of a metabolite of sulfur mustard (HD), namley bis(2-acetylamino-2-carboxyethylthio)ethyl) sulfoximine, (dimercapturate)2S(O)Nhwill be synthesized. This will be conjugated with proteins to yield the antigenic haptens… More

Epitope driven HPV Vaccine Targeting Dentritic Cells

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$247,768.00
Agency:
HHS
Principal Investigator:
Anne S. Degroot
Abstract:
Human Papilloma Virus (HPV) types 16 and 18 are detected in roughly 70% of all invasive cervical tumors. Among cytologically normal women, detection of HPV infection by PCR has been shown to increase the subsequent risk of cervical cytologic abnormalities by 12 fold, suggesting that effective… More

Diagnostic Reagents for Emerging Infectious Diseases

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$105,609.00
Agency:
HHS
Principal Investigator:
Anne S. Degroot
Abstract:
DESCRIPTION (provided by applicant): West Nile virus (WNV) is a flavivirus commonly found in Africa, West Asia, and the Middle East. The virus was introduced into the United States in 1999. Case-fatality rates during the 1999-2000 U.S. epidemics ranged from 3… More

A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$831,922.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): EpIVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we describe a rapid approach to the development of a tularemia vaccine that could be for BioDefense. First, F.… More

A Genome-Derived, Epitope-Driven H. Pylori Vaccine

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$609,910.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based approach for the development of a therapeutic vaccine against Helicobacter pylori disease. First, the H.… More

Novel Smallpox Vaccine Derived from VV/VAR Immunome

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$1,027,407.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to develop a safe, new smallpox vaccine based on epitopes conserved between the vaccinia virus (VV) and… More

Optimization of a Multivalent Tuberculosis Vaccine

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$590,912.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit immunity to prevent reactivation of latent TB. This epit ope-driven, DNA-prime, protein-boost TB… More

Epitope-driven deimmunization of Factor VIII

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$528,313.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophiliacs and greater than 50% of severe hemophiliacs produce antibodies (inhibitors) in response to… More

T1D Tolerance Induction with Natural Treg Epitopes

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$599,999.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet cell antigen-specific T cells are either deleted in thymic development or are converted to T… More

EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,474,236.00
Agency:
HHS
Principal Investigator:
Anne S. Degroot – 401-272-2123
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of… More

Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Anne S. Degroot – 401-272-2123
Abstract:
DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affectingheart and skeletal muscle.… More

Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$757,712.00
Agency:
HHS
Principal Investigator:
Anne S. Degroot – 401-272-2123
Abstract:
DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance induction at therapeutic doses for Hemophilia A patients. Hemophiliacs with lt 1% functional FVIII… More